Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Lymphocytic Leukemia, Chronic
Both
Lymphocytic Leukemia, Chronic
Trial Information
Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera
Inclusion Criteria:
- Adult patients, >/=18 years of age
- Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) with first or
second relapse
- Previous treatment with MabThera/Rituxan
- MabThera/Rituxan treatment planned for current relapse
Exclusion Criteria:
- Richter syndrome
- Life expectancy <6 months
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Chemotherapy regimens associated with MabThera/Rituxan in management of relapse/refractory CLL: Percentage of patients receiving purine analogues/bendamustine/alkylating agents/other chemotherapy
Outcome Time Frame:
2 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
ML25664
NCT ID:
NCT01488162
Start Date:
April 2011
Completion Date:
July 2016
Related Keywords:
- Lymphocytic Leukemia, Chronic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Chronic Disease
Name | Location |
|---|
